Small fiber neuropathy

Cover Page

Abstract

Despite the fact that small fiber neuropathy (SFN) has already been studied for 30 years, it remains one of the most mysterious diseases that are extremely difficult to diagnose and cure. The prevalence of SFN is 52.95 per 100,000 population; diabetes mellitus is considered to be the most frequent cause of this disease. Chronic neuropathic pain syndrome, temperature sensation abnormalities, and vegetative disorders develop as a result of damage to fine myelinated Аδ- and unmyelinated C fibers. The disease mainly spreads in the upward direction: from feet to the proximal body parts and arms; primary axonal damage takes place. Although SFN is believed to be one of the most “benign” neuropathy types as it does not affect the large sensory and motor fibers, it significantly decreases patients’ quality of life.

About the authors

N. A. Suponeva

Research Center of Neurology, Moscow

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

N. V. Belova

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

N. I. Zaitseva

Lomonosov Moscow State University, Moscow

Email: platonova@neurology.ru
Russian Federation

D. G. Yusupova

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

D. Yu. Lagoda

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

O. S. Korepina

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

M. A. Piradov

Research Center of Neurology, Moscow

Email: platonova@neurology.ru
Russian Federation

References

  1. Vinik A., Ullal J., Parson H.K., Casellini C.M. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006; 2: 269–81. doi: 10.1038/ncpendmet0142. PMID: 16932298.
  2. Loseth S., Stalberg E., Jorde R., Mellgren S.I. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies. J Neurol. 2008; 255: 1197–202. doi: 10.1007/s00415-008-0872-0. PMID: 18574618.
  3. Malik R.A., Veves A., Tesfaye S. et al. Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diabetes Metab Res Rev. 2011;27: 678–84. doi: 10.1002/dmrr.1222. PMID: 21695760.
  4. Serra J., Collado A., Sola R. et al. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol. 2014; 75: 196–208. doi: 10.1002/ana.24065. PMID: 24243538.
  5. Van Acker N., Rage M., Slyudts E. et al. Automated PGP9.5 immunofluorescence staining: a valuable tool in the assessment of small fiber neuropathy? BMC Res Notes. 2016; 9: 280. doi: 10.1186/s13104-016-2085-4. PMID: 27215701.
  6. Dyck P.J. Incidence and prevalence of small-fiber neuropathy: A survey in the Netherlands. Neurology. 2014; 82; 1385. doi: 10.1212/01. wnl.0000446502.87636.91. PMID: 24733860.
  7. Peters M.J., Bakkers M., Merkies I.S. et al. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology. 2013; 81: 1356–1360. doi: 10.1212/WNL.0b013e3182a8236e. PMID: 23997150.
  8. Chan A., Wilder-Smith E. Clinical reasoning: burning hands and feet. Neurology. 2015; 84: e146-152. doi: 10.1212/WNL.0000000000001559. PMID: 25964484.
  9. Oh S.J., LaGanke C., Claussen G.C. Sensory Guillain-Barre syndrome. Neurology. 2001; 56: 82–86. PMID: 11148240.
  10. Suponeva N.A., Pavlov Y.V. [Diagnosis and basic therapy of chronic polyneuropathies]. Vrach. 2009; 9: 43–44. (In Russ.)
  11. Smith A.G., Singleton J.R. Impaired glucose tolerance and neuropathy. Neurologist. 2008; 14(1): 23–29. doi: 10.1097/NRL.0b013e31815a3956. PMID: 18195653.
  12. Smith A.G. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. J Peripher Nerv Syst. 2012; 17(suppl 2): 15–21. doi: 10.1111/j.1529-8027.2012.00390.x. PMID: 22548618.
  13. Chao C.C., Wu V.C., Tan C.H. et al. Skin denervation and its clinical significance in late-stage chronic kidney disease. Archives of Neurology. 2011; 68: 200–206. doi: 10.1001/archneurol.2010.372. PMID: 21320986.
  14. McManis P.G., Windebank A.J., Kiziltan M. Neuropathy associated with hyperlipidemia. Neurology. 1994; 44: 2185–2186. PMID: 7969981.
  15. Vas P.R., Sharma S., Rayman G. LDI flare small fiber function in normal glucose tolerant subjects with and without hypertriglyceridemia. Muscle Nerve. 2015; 52: 113–119. doi: 10.1002/mus.24504. PMID: 25363244.
  16. Boger M.S., Hulgan T., Haas D.W. et al. Measures of small-fiber neuropathy in HIV infection. Autonomic Neuroscience. 2012; 169: 56–61. DOI: 10.1016/j. autneu.2012.04.001. PMID: 22542355.
  17. Herrmann D.N., McDermott M.P., Sowden J.E. et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neu-rology. 2006; 66: 857–861. doi: 10.1212/01.wnl.0000203126.01416.77. PMID: 16567702.
  18. Mah V., Vartavarian L.M., Akers M.A., Vinters H.V. Abnormalities of peripheral nerve in patients with human immunodeficiency virus infection. Ann Neurol. 1988; 24(6): 713–7. doi: 10.1002/ana.410240604. PMID: 2849921.
  19. Oaklander A.L., Herzorg Z.D., Downs H.M., Klein M.M. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013; 154: 2310–2316. doi: 10.1016/j.pain.2013.06.001. PMID: 23748113.
  20. Gemignani F. Fibromyalgia syndrome and small-fiber neuropathy. Ann Neurol. 2014; 76: 916. doi: 10.1002/ana.24269. PMID: 25186210.
  21. de Araújo F., de Melo Neto A.P., Oliveira I.S. et al. Small (autonomic) and large fiber neuropathy in Parkinson disease and Parkinsonism. Neurology. 2016; 16: 139. doi: 10.1186/s12883-016-0667-3. PMID: 27530902.
  22. Mohammad A. Assessment of Small Fiber Neuropathy. JAMA Neurology. Published online April 11, 2016.
  23. Gibbons C.H. Small fiber neuropathies. Continuum (Minneap Minn). 2014; 20(5): 1398–1412. doi: 10.1212/01.CON.0000455874.68556.02. PMID: 25299289.
  24. McArthur J.C. Painfull small fiber neuropathies. Continuum Lifelong Learning Neurol. 2012; 18(1):106–125. doi: 10.1212/01.CON.0000411570.79827.25. PMID: 22810072.
  25. Sumner C.J., Sheth S., Griffin J.W. et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003; 60: 108–111. PMID: 12525727.
  26. EFNS Clinical Recommendations. 2012 (1). Edited by N.E. Gilhus, M.P. Barnes, M. Brainin. Scientific Russian editor – S.S. Nikitin. Second edition. Publishing house «АВV-press». (In Russ.)
  27. Quattrini C, Tavakili M., Jeziorska M. et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007; 56: 2148–54. doi: 10.2337/db07-0285. PMID: 17513704.
  28. Tavee J., Zhou L. Small fiber neuropathy: a burning problem. Cleveland Clinic Journal of Medicine. 2009; 76(5): 297–305. doi: 10.3949/ccjm.76a.08070. PMID: 19414545.
  29. Umapathi T., Tan W.L., Loke S.C. et al. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve. 2007; 35: 591–8. doi: 10.1002/mus.20732. PMID: 17221881.
  30. Devigili G., Tugnoli V., Penza P. et al. The diagnostic criteria for small fiber neuropathy: from symptoms to neuropathology. Brain. 2008; 131: 1912–1925. doi: 10.1093/brain/awn093. PMID: 18524793.
  31. McArthur J.C., Stocks E.A., Hauer P. et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol. 1998; 55: 1513–1520. PMID: 9865794.
  32. Hoeijmakers J.G., Faber C.G., Miedema C.J. et al. Small Fiber Neuropathy in Children: Two Case Reports Illustrating the Importance of Recognition. Pediatrics. 2016; 138(4): e20161215. doi: 10.1542/peds.2016-1215. PMID: 27660061.
  33. Latronico N., Filosto M., Fagoni N. et al. Small Nerve Fiber Pathologyin Critical Illness. PLoS ONE. 2013; 8(9): e75696. doi: 10.1371/journal. pone.0075696. PMID: 24098716.
  34. Oaklander A.L., Klein M.M. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. Pediatrics. 2013; 131: e1091–1100. doi: 10.1542/peds.2012-2597. PMID: 23478869.
  35. Dyck P.J., Kincaid J.C., Chaudhry V. et al. Assessing mNIS+7Ionis and International Neurologists’ Proficiency in an FAP Trial. Muscle & Nerve. Accepted article. doi: 10.1002/mus.25563. PMID: 28063170.
  36. Mantyh G., Dyck P.J., Dyck P.J. et al. Epidermal Nerve Fiber Quantification in Patients With Erythromelalgia. JAMA Dermatol. Published online December 7, 2016. doi: 10.1001/jamadermatol.2016.4404.
  37. Shy M.E., Frohman E.M., So Y.T. et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003; 60: 898–904. PMID: 12654951.
  38. Thaisetthawatkul P., Fernandes Filho J.A., Hermann D.N. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve. 2013; 48: 883–888. doi: 10.1002/mus.23891. PMID: 23649502.
  39. Vinik A.I., Casellini C., Nevoret M.L. Alternative Quantitative Tools in the Assessment of Diabetic Peripheral and Autonomic Neuropathy. International Review of Neurobiology. Article in press. doi: 10.1016/bs.irn.2016.03.010. PMID: 27133153.
  40. Ebadi H., Siddiqui H., Ebadi S. et al. Peripheral nerve ultrasound in small fiber polyneuropathy. Ultrasound in Medicine & Biology. 2015; 41(11): 2820–2826. doi: 10.1016/j.ultrasmedbio.2015.06.011. PMID: 26318562.
  41. Brouwer B.A., Bakkers M., Hoeijmakers J.G. et al. Improving assessment in small fiber neuropathy. Journal of Peripheral Nervous System. 2015; 20: 333–340. doi: 10.1111/jns.12128. PMID: 26114213.
  42. Singleton J.R., Bixby B., Russell J.W. et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008; 13: 218–227. doi: 10.1111/j.1529-8027.2008.00180.x. PMID: 18844788.
  43. Bakkers M., Faber C.G., Hoeijmakers J.G. et al. Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve. 2014; 49: 329–336. PMID: 23716362. doi: 10.1002/mus.23910.
  44. Lauria G., Merkies I.S., Faber C.G. Small fibre neuropathy. Curr Opin Neurol 2012; 25: 542–549. doi: 10.1097/WCO.0b013e32835804c5. PMID: 22941266.
  45. González-Duarte A., Lem M., Diaz-Diaz E. et al. Efficacy of Pregabalin in the treatment of prediabetic neuropathic pain. The Clinical Journal of Pain Publish Ahead of Print. 2016; 32(11): 927–932. doi: 10.1097/AJP.0000000000000339. PMID: 26670614.
  46. Acevedo J.C., Amaya A., Casasola Ole L. et al. Guidelines for the diagnosis and management of neuropathic pain: consensus of a group of Latin American experts. Journal of Pain and Palliative Care Pharmacotherapy. 2009; 23: 261–281. doi: 10.1080/15360280903098572. PMID: 19670022.
  47. Bohlega S., Alsaadi T., Amir A. et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the Middle East region. Journal of International Medical Research. 2010; 38: 295–317. PMID: 20515552.
  48. Bril V., England J., Franklin G.M. et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM&R. 2011; 3: 345. doi: 10.1212/WNL.0b013e3182166ebe. PMID: 21482920.
  49. Dworkin R.H., O'Connor A.B., Audette J. et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings. 2010; 85: 14. doi: 10.4065/mcp.2009.0649. PMID: 20194146.
  50. Moulin D., Boulanger A., Clark A.J. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19: 328–335. PMID: 25479151.
  51. Desai B., Freeman E. Huang E. et al. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. Expert Review of Clinical Pharmacology. 2014; 7(2): 203- 9. doi: 10.1586/17512433.2014.889562, PMID: 24524594.
  52. Games G., Hutchison A. Tapentadol-ER for the treatment of diabetic peripheral neuropathy. Consult Pharm. 2013; 28: 672–675. doi: 10.4140/TCP.n.2013.672. PMID: 24129223.
  53. Dabby R., Gliad R., Sadeh M. et al. Acute steroid responsive small-fiber sensory neuropathy: a new entity? Journal of Peripheral Nervous System. 2006; 11: 47–52. doi: 10.1111/j.1085-9489.2006.00062.x. PMID: 16519781.
  54. Orstavik K., Norheim I., Jorum E. Pain and small-fiber neuropathy in patients with hypothyroidism. Neurology 2006; 67: 786–791. doi: 10.1212/01. wnl.0000234035.13779.4a. PMID: 16966538.
  55. Parambil J.G., Tavee J.O., Zhou L. et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med. 2011; 105 (1): 101–5. doi: 10.1016/j.rmed.2010.09.015. PMID: 20926271.
  56. Souayah N., Chin R.L., Brannagan T.H. et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol. 2008; 15(12): 1300–3. doi: 10.1111/j.1468-1331.2008.02305.x. PMID: 19049545.
  57. Wakasugi D., Kato T., Gono T. et al. Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome. Mod Rheumatol. 2009; 19 (4): 437–40. doi: 10.1007/s10165-009-0180-2. PMID: 19458906.
  58. Chan A., Wilder-Smith E.P. Small fiber neuropathy: getting bigger! Muscle Nerve. 2016; 53: 671–682. doi: 10.1002/mus.25082. PMID: 26872938.
  59. Goebel A. Immunoglobulin responsive chronic pain. J Clin Immunol. 2010; 30 Suppl 1: S103-8. doi: 10.1007/s10875-010-9403-8. PMID: 20424897.
  60. de Greef B.T., Geerts M., Hoeijmakers J.G. et al. Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial. Trials. 2016; 17: 330. doi: 10.1186/s13063-016-1450-x.

Statistics

Views

Abstract: 1505

PDF (Russian): 976

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Suponeva N.A., Belova N.V., Zaitseva N.I., Yusupova D.G., Lagoda D.Y., Korepina O.S., Piradov M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies